Complications associated with oncological therapy - how to minimize?
Keywordschemotherapy, toxicity, pain treatment, oncology, disorders
During cancer therapy, patients undergo long-term treatment with chemotherapists. Unfortunately, although chemotherapy effectively destroys cancer cells, its toxicity may cause many adverse effects, weakening the patient's body. Their intensity is determined by many factors, including the age of the patient, the dose and type of drugs, the efficiency of metabolism and the occurrence of coexisting diseases. The most common side effects associated with chemotherapy include: myelosuppression, anaemia, neutropenia, thrombocytopenia, thrombocytopenia, thromboembolic disease, cardiovascular disorders, hair loss, nausea, diarrhoea, mucositis, taste change or fatigue.The complications that occur during or after chemotherapy are still a huge challenge for modern oncology. It is very important that the treatment of a patient with cancer is conducted by a team of doctors with many specializations. The individualization of treatment and the introduction of combined therapy may significantly minimize the occurrence of many serious complications, which may affect not only the quality of treatment, but also the patient life expectancy.
Radziwon P, Krzakowski M, Kalinka-Warzocha E, Zaucha R, Wysocki P, Kowalski D, et al. Anemia in cancer patients — Expert Group recommendations. 2017;3.
Dale D. Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors. Semin Oncol 2003;30:3-9.
Schiffer CA, Bohlke K, Delaney M, Hume H, Magdalinski AJ, McCullough JJ, et al. Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2018;36:283-299.
Rapoport BL. Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management. Front Pharmacol 2017;8.
Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100:2026-46.
Busti F, Marchi G, Ugolini S, Castagna A, Girelli D. Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. Pharmaceuticals 2018;11.
Bormanis J, Quirt I, Chang J, Kouroukis CT, MacDonald D, Melosky B, et al. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)? Crit Rev Oncol Hematol 2013;87:132-9.
de Putter R, Geboes K, De Man M, Van Belle S. Treatment of anemia in patients with solid tumors receiving chemotherapy in palliative setting: usual practice versus guidelines. Acta Clin Belg 201;73:251-256.
Benichou C, Solal Celigny P. Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting. Nouv Rev Fr Hematol 1991;33:257-62.
Soff J, Bussel J. TPO-mimetics for chemotherapy-induced thrombocytopenia: timing matters. Leuk Lymphoma 2018:59:2763-2764.
Zhang X, Chuai Y, Nie W, Wang A, Dai G. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours. Cochrane Database Syst Rev 2017;11:Cd012035.
Wilde MI, Faulds D. Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs 1998;10:159-71.
Lyman GH, Allcott K, Garcia J, Stryker S, Li Y, Reiner MT, Weycker D. The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. Support Care Cancer 2017;25:2619-2629.
Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-15.
Singh G, Rathi AK, Singh K, Sharma D. Venous thromboembolism in cancer patients - magnitude of problem, approach, and management. Indian J Cancer 2017:54:308-312.
Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost 2017;117:219-230.
Donnellan E, Khorana AA. Cancer and Venous Thromboembolic Disease: A Review. Oncologist 2017;22:199-207.
Navari RM. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf 2016;15:343-56.
Aapro M. 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology 2005;69:97-109.
de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4105-11.
Clarkson JE, Worthington HV, Furness S, McCabe M, Khalid T, Meyer S. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2010;Cd001973.
Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician, Clin Med Insights Cardiol 2019;13.
Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23(7):155-66.
Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin 2016;66:309-25.
Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005;23:2900-2.
Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, et al. Assessment of pain. Br J Anaesth 2008;101:17-24.
Chien CW, Bagraith KS, Khan A, Deen M, Strong J. Comparative responsiveness of verbal and numerical rating scales to measure pain intensity in patients with chronic pain. J Pain 2013;14:1653-62.
Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, et al. Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage 2011;41:1073-93.
Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23(7):139-54.
Wordliczek J, Kotlinska-Lemieszek A, Leppert W, Woron J, Dobrogowski J, Krajnik M, et al. Pharmacotherapy of pain in cancer patients - recommendations of the Polish Association for the Study of Pain, Polish Society of Palliative Medicine, Polish Society of Oncology, Polish Society of Family Medicine, Polish Society of Anaesthesiology and Intensive Therapy and Association of Polish Surgeons. Pol Przegl Chir 2018;90:55-84.
Forbes K. Pain in patients with cancer: the World Health Organization analgesic ladder and beyond, Clin Oncol (R Coll Radiol) 2011;23:379-80.
How to Cite
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 216
Number of citations: 0